Inclusion Criteria

1. The patient has histologically or cytologically confirmed clear cell RCC.
2. The patient is ≥ 18 years of age.
3. The patient has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1 or Karnofsky Performance Status (KPS) ≥ 80%.
4. The patient has had a prior nephrectomy (as therapy for RCC).
5. The patient has metastatic RCC.
6. The patient has a life expectancy of > 3 months.
7. The patient has measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST).
8. The patient has received prior therapy with a TKI (sunitinib and/or sorafenib) with either disease progression on TKI therapy (progression within 60 days of the last dose of TKI) or intolerance to TKI (unable to continue therapy because of side-effects). A patient with progression during a protracted treatment break is not eligible unless the patient has had progression or intolerance as defined above.
9. The patient has resolution of all clinically significant toxic effects of prior cancer therapy to grade ≤ 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 (NCI-CTCAE).
10. The patient has adequate hematological functions (absolute neutrophil count [ANC] ≥ 1500 cells/mL, hemoglobin ≥ 9 g/dL and platelets ≥ 100,000 cells/mL).
11. The patient has adequate hepatic function (bilirubin within normal limits [WNL], aspartate transaminase [AST] and/or alanine transaminase [ALT] ≤ 2.5 times the upper limit of normal [ULN], or ≤ 5.0 times the ULN if the transaminase elevation is due to liver metastases).
12. The patient has normal renal function or mild renal dysfunction (creatinine ≤ 2.2 mg/dL).
13. The patient's urinary protein ≤ 1+ on dipstick or routine urinalysis ([UA]; if urine dipstick or routine analysis is ≥ 2+, a 24-hour urine for protein must demonstrate < 1000 mg of protein in 24 hours to allow participation in the study).
14. The patient must have adequate coagulation function as defined by International Normalized Ratio (INR) ≤ 1.8 and a partial thromboplastin time (PTT) ≤ 1.5 X ULN. Patients on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight (LMW) heparin and if on warfarin must have a INR between 2 and 3 and have no active bleeding or pathological condition that carries a high risk of bleeding (eg, tumor involving major vessels or known varices).
15. The patient is able to provide informed written consent.
16. The patient, if sexually active, is postmenopausal (last menstrual period > 2 years prior to study), surgically sterile, or is using effective method of contraception in the opinion of the investigator.
17. The patient, if female, must have a negative serum pregnancy test upon entry into this study.
18. The patient has a normal thyroid stimulating hormone (TSH) value. Patients with an abnormal TSH may be eligible provided they meet all other eligibility criteria and have ECOG performance status 0-1. Patients with an abnormal TSH value require a full thyroid evaluation prior to enrollment. Endocrinology consultation may be performed at the discretion of the investigator.
19. The patient has serum calcium within normal limits.

Exclusion Criteria

1. The patient has received prior treatment with bevacizumab.
2. The patient has known brain or leptomeningeal metastases.
3. The patient has received prior chemotherapy for RCC.
4. The patient has received antitumor therapy (biologic agents, major surgery, or investigational agent) within 28 days prior to enrollment on study. The patient has received radiation therapy within 14 days prior to enrollment on study. Patients with metastasis in weight bearing bones at high risk for pathologic fracture may participate provided that appropriate surgical intervention and/or radiation therapy is undertaken and completed at least 28 days prior to enrollment.
5. The patient has received > 1 prior bioimmunotherapy regimens (defined as either interleukin-2 or interferon alpha given as monotherapy, concurrently, or sequentially as planned).
6. The patient has a concurrent active malignancy other than adequately treated non-melanomatous skin cancer or other non-invasive carcinoma or in situ neoplasm. A patient with previous history of malignancy is eligible, provided that he/she has been disease free for > 3 years.
7. The patient has a nonhealing wound or ulcer.
8. The patient has a known alcohol or drug dependency.
9. The patient is pregnant or breastfeeding.
10. The patient has a coexisting medical or psychiatric problem of sufficient severity to limit compliance with the study and/or increase the risks associated with study participation or study drug administration or interfere with the interpretation of study results.
11. The patient has an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders in the opinion of the investigator.
12. The patient has known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness.